IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
about
Cancer genome landscapesMolecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and diseaseIDH1 and IDH2 mutations in gliomasBrainstem Glioma in AdultsFundamentals of cancer metabolismTargeting histone methylation for cancer therapy: enzymes, inhibitors, biological activity and perspectivesMetabolic, autophagic, and mitophagic activities in cancer initiation and progressionEpigenetic therapy in gastrointestinal cancer: the right combinationMitochondrial metabolic remodeling in response to genetic and environmental perturbationsPhysiological and pathological implications of 5-hydroxymethylcytosine in diseasesMolecular Imaging of Metabolic Reprograming in Mutant IDH CellsDysregulated metabolism contributes to oncogenesisIn vivo models of brain tumors: roles of genetically engineered mouse models in understanding tumor biology and use in preclinical studiesMolecular characterizations of glioblastoma, targeted therapy, and clinical results to dateNF-κB and STAT3 in glioblastoma: therapeutic targets coming of ageMechanisms of epigenetic regulation of leukemia onset and progressionExtracellular vesicles as a platform for 'liquid biopsy' in glioblastoma patientsNew developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in gliomaEpigenetic dysregulation: a novel pathway of oncogenesis in pediatric brain tumorsApplication of metabolomics in drug resistant breast cancer researchIDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in gliomaDNA methylation data analysis and its application to cancer researchMolecular biology of gliomas: present and future challengesOligodendroglioma: pathology, molecular mechanisms and markersBrain tumor stem cells: Molecular characteristics and their impact on therapyGenetically-defined metabolic reprogramming in cancerNovel therapeutic targets of tumor metabolismDeveloping epigenetic diagnostics and therapeutics for brain disordersChromatin signatures of cancerFueling immunity: insights into metabolism and lymphocyte functionContemporary murine models in preclinical astrocytoma drug developmentSurvivin promotes oxidative phosphorylation, subcellular mitochondrial repositioning, and tumor cell invasionCrystallographic Investigation and Selective Inhibition of Mutant Isocitrate DehydrogenaseTargeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiationDNA methylation changes in epithelial ovarian cancer histotypes.IDH mutations in tumorigenesis and their potential role as novel therapeutic targets.New IDH1 mutant inhibitors for treatment of acute myeloid leukemiaAn inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis.IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives
P2860
Q22242276-11BD6808-F24A-4ED1-AB24-3634890BB640Q24289344-C6337D53-8396-420A-B4BF-C4E3C84BFCC1Q24561928-D3DA1B51-837B-47E1-A428-DFC46F60688DQ26739232-94BCAF2F-3626-4C57-ADDC-C330696DA206Q26744062-9AC41B59-F820-449B-8DB3-34AC37E6AB47Q26744441-EA6A97D0-985B-4E37-AB0A-3EF0A9F14874Q26745503-F3B3749F-ABD5-4FC6-AF04-0EF9B0574B9AQ26745709-D55AD394-26F8-4DD5-92A6-871A17646D35Q26747718-F5DE2B26-9441-44CE-8CB4-FED256B4969FQ26749375-9424599B-8A83-448F-958A-9CF31C8D3DD2Q26750861-3C23EFB8-7687-4152-B4FD-71E6A9776611Q26784630-51158B02-09EC-43D1-9974-BFCF041F1549Q26820289-162C3B8E-3B65-4E5B-9903-0163819192ABQ26822717-F2DEA60E-7A99-4F7C-87E2-D8DD3DAFCAC8Q26830388-196DB540-7087-4653-B652-D6FEE188A08FQ26861785-A9993CB6-5C47-4D87-80D0-D1084930B988Q26861832-60CC3F07-5698-4A7E-AE07-18D1A3470122Q26863394-A9E5017A-2F80-4250-9F11-2E0B2D4EAD35Q26864920-5B8F2099-0D97-40EB-A521-7E81228F8D82Q26866291-E4142611-1244-4F1E-9E2A-8461B837AA33Q26995506-9DC8DC28-BA6A-4F57-8ADB-82A7434577E5Q26996466-FF138CE4-7056-466C-8A33-523938E97A89Q27001295-9FA4ABDF-71BB-4C72-B8FF-A486FC95736AQ27002448-6067A06E-8970-4410-B4C4-E58FAAEB3FB3Q27003138-7F44E23E-C7F2-484A-A476-261F9D6D5D2EQ27004739-19877EA6-B16F-45B0-B21C-722EF8A1728DQ27005930-F0F9E57B-8B6A-4BC9-B34F-84143538FC2FQ27022987-AC34F1AA-3673-41D5-974A-A73B237319C0Q27024162-37A0B6AB-8BD4-45EC-AED8-E56A17CA1076Q27025284-FCDB89DF-834A-4BD0-AF15-FBAC08433A0EQ27026937-751C80F2-F120-4972-874B-A231B655513CQ27329571-1E7D7662-0E51-42AF-AA18-D557B542B8F2Q27678755-33402AB5-584C-4BB4-A8F3-D9680B403348Q27684364-CB17F4CC-A344-48CA-95A4-02C014957F87Q27690722-FD605312-AB85-4D1F-B6E7-84546E9885C3Q27692015-B6040A28-8DCF-4AEC-8F24-B43E3900E168Q27702240-0D84FAE9-5594-45B0-99D1-995BC058B9A3Q27852141-5316FACC-B385-4FB7-A618-6ABFA96D05C3Q27852494-C1A55764-6ACA-41C0-948B-BE360F9A6849Q28066926-B50F4B3B-476D-4C6C-B558-E5FB665324ED
P2860
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
description
2012 nî lūn-bûn
@nan
2012 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
@ast
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
@en
type
label
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
@ast
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
@en
prefLabel
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
@ast
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
@en
P2093
P2860
P3181
P356
P1433
P1476
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
@en
P2093
Guryanova O
P2860
P2888
P304
P3181
P356
10.1038/NATURE10866
P407
P577
2012-02-15T00:00:00Z
P5875
P6179
1010733927